Oxford Biomedica (LSE: OXB) a leading gene therapy company, announced today its unaudited interim financial results for the six months ended 30 June 2008. Year to date highlights:

Operational

TroVax^® (multiple cancers)

Milestone payment of €10 million from sanofi-aventis

  Encouraging Phase II results in renal cancer and colorectal cancer published

  Completed recruitment of 733 patients in Phase III TRIST study

DSMB stated that TRIST study would not meet primary endpoint but should be continued without further vaccinations

FDA meeting scheduled in October 2008 to discuss TRIST data and study amendments

Sanofi-aventis expected to start Phase III trials in colorectal cancer, pending outcome of FDA meeting

QUASAR group committed to 3,000-patient study in adjuvant colorectal cancer

ProSavin^® (Parkinson's disease)

Treatment is safe and well tolerated in first cohort of patients in Phase I/II trial

Preparing for Phase III development

RetinoStat^® (age-related macular degeneration)

Preparing regulatory submission to start Phase I/II trial

Other

  Secured rights to therapeutic use of Nobel Prize-winning RNAi technology

Board changes

  Dr Alex Lewis appointed as Non-Executive Director

  Professor Alan Kingsman succeeded Dr Peter Johnson as Chairman

Dr Stuart Naylor succeeded Dr Susan Kingsman as Chief Scientific Officer

Nick Woolf appointed to new position of Chief Business Officer

Dr Mike McDonald, Chief Executive Officer, left the Board

  John Dawson, Non-Executive Director, appointed as Acting Chief Executive Officer

Strategic restructuring

  Cost savings estimated to extend cash for operations through first half of 2010